It has been shown that many proteins are functionally related to cancerogenesis. Reliable quantification of these proteins, so called biomarkers,
in human serum or tissue biopsy samples represents a way to assess better diagnosis and improve patient outcome. Moreover, small molecule drugs inhibiting
biological function of these proteins are also used in cancer therapy. Here we present a newly developed assay, called DIANA, which is capable of both
selective protein detection and screening of small molecule inhibitors of those proteins.
DIANA is a multiwell-plate based sandwich ELISA-like dual recognition assay, suitable for protein detection and screening of protein ligands that employs
a fully synthetic detection probe. This probe is constructed from small molecule active site ligand and it consequently binds into the active site of the target protein.
Advantages of DIANA for protein detection:
- Sensitivity: up to zeptomolar (10-21 M) amounts of target proteins are detected
- Selectivity: target proteins are selectively quantified in biological matrices (blood serum, urine, cell lysate)
- Broad linear range of up to six-logs
Advantages of DIANA for screening of small molecule ligands:
- Sensitivity: only small amounts (typically pictogram) of protein needed for screening
- Selectivity: no need for recombinant and/or purified proteins
- Dissociation constant can be determined from a single tested concentration
As we have shown on two proteins, DIANA has proven to be a excellent method for protein detection which is characterized by superior sensitivity, broad linear range and
high selectivity. Additionally, it has two more unique advantages over most widely used sandwich immunoassays such as ELISA, immuno-PCR and proximity ligation/extension
assay. Since the probe binds to the target at a defined site via small molecule ligand, the selectivity of binding of the probe can be always tested by titration with
the free ligand. Moreover, in contrast to the sandwich immunoassays, this assay is not prone to false positive results due to interfering antibodies present in human
blood and is therefore best suitable for use in in vitro diagnostics.
Read more at IOCB TTO website.